Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors.

ABSTRACT:

Importance

Two prominent organizations, the American Society of Clinical Oncology and the National Quality Forum (NQF), have developed a cancer quality metric aimed at reducing systemic anticancer therapy administration at the end of life. This metric, NQF 0210 (patients receiving chemotherapy in the last 14 days of life), has been critiqued for focusing only on care for decedents and not including the broader population of patients who may benefit from treatment.

Objective

To evaluate whether the overall population of patients with metastatic cancer receiving care at practices with higher rates of oncologic therapy for very advanced disease experience longer survival.

Design, setting, and participants

This nationwide population-based cohort study used Flatiron Health

SUBMITTER: Canavan ME 

PROVIDER: S-EPMC11099840 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature